single-blind, placebo-controlled,rising-dose study, eight patients re-ceived four escalating single doses ofexenatide (Amylin Pharmaceuticals)or placebo. Patients were instructedto stop OAA treatment 14 days be-fore day 1 and for the duration of thestudy. Patients were randomized toone of four treatment sequences con-sisting of a single dose of each of thefollowing: placebo, 0.1  µg/kg ex- enatide, 0.2 µg/kg exenatide, 0.3 µg/ kg exenatide, and either 0.4 µg/kg ex-